Addressing disease heterogeneity in myotonic dystrophy. Towards personalized intervention.

10 June 2021

Delivered by Alain Geille, (president Euro-DyMA), Peter-Bram ‘t Hoen and Baziel van Engelen

Jun 10, 2021 16:00 Paris time

 

This seminar will focus on the development of individualized interventions in myotonic dystrophy that take into account the clinical heterogeneity between patients and that meet personalized treatment goals.
The topic will be addressed from the the patient perspective (interview by Alain Geille, president Euro-DyMA), the perspective of a clinician and clinical researcher (Prof. Baziel van Engelen, Neurology, Radboudumc) and a basic researcher (Prof. Peter-Bram ‘t Hoen, Bioinformatics, Radboudumc). Experiences and lessons from the OPTIMISTIC trial with Cognitive Behavioural Therapy as a personalized intervention will be shared. Molecular biomarker signatures associated with heterogeneity in clinical phenotypes and how this motivates development of drug repurposing strategies in the ReCognitION project will be presented.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern